Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 4.
doi: 10.1038/s41416-025-03073-7. Online ahead of print.

Cancer of unknown primary: the hunt for its elusive tissue-of-origin - is it time to call off the search?

Affiliations
Review

Cancer of unknown primary: the hunt for its elusive tissue-of-origin - is it time to call off the search?

Laura Spurgeon et al. Br J Cancer. .

Abstract

Cancer of Unknown Primary (CUP) is an heterogenous group of metastatic cancers, for which the primary site cannot be identified despite thorough diagnostic work-up. Whilst it is a relatively rare entity, its aggressive nature, together with the paucity of effective treatments, mean it has a disproportionately high mortality rate. Advances in genomic profiling have driven research in the area, but despite this, therapeutic options and prognosis remain poor. For many years, the primary focus in CUP has been improving identification of the tissue-of-origin (TOO), with the hope that site-specific therapy will improve survival outcomes. However, the lack of conclusive evidence to support this, as well as an emerging paradigm shift in how cancers should be classified, has reignited the debate surrounding the importance of TOO. Here, we provide a comprehensive review of the ongoing relevance of TOO, within both the CUP and wider oncology landscape.

PubMed Disclaimer

Conflict of interest statement

Competing interests: NC has received consulting fees from Roche Pharmaceuticals, Servier and REDX Pharmaceuticals; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Roche Pharmaceuticals; support for attending meetings and/or travel from Roche Pharmaceuticals; research funding to research team from AstraZeneca, Orion, F. Hoffmann-La Roche Ltd, Taiho, Novartis, Starpharma, Bayer, Eisai, UCB, RedX Pharmaceuticals, LOXO-oncology, Avacta, Boehringer Ingelheim, Merck and Tarveda Therapeutics; participated in data safety monitoring board or advisory board at Roche Pharmaceuticals and Cancer Research UK. AMC has received support for attending meetings and/or travel from Roche Products Limited, and is a named inventor on a patent registered by “Cancer Research Technology Ltd”. LS and CM declare no potential competing interests.

Similar articles

References

    1. Cancer Research UK [CRUK]. Cancer of unknown primary (online). Available via: https://www.cancerresearchuk.org/about-cancer/cancer-unknown-primary-cup... (2024). Accessed January 2025.
    1. Qaseem A, Usman N, Jayaraj JS, Janapala RN & Kashif T. Cancer of Unknown Primary: A Review on Clinical Guidelines in the Development and Targeted Management of Patients with the Unknown Primary Site. Cureus (2019). https://doi.org/10.7759/cureus.5552 .
    1. Cancer Research UK [CRUK]. Cancer of unknown primary (online). Available via: https://www.cancerresearchuk.org/about-cancer/cancer-unknown-primary-cup... (2017). Accessed January 2025.
    1. Alshareeda AT, Al-Sowayan BS, Alkharji RR, Aldosari SM, Al Subayyil AM, Alghuwainem A. Cancer of Unknown Primary Site: Real Entity or Misdiagnosed Disease? J Cancer. 2020;11:3919–31. - PubMed - PMC - DOI
    1. National Institute for Clinical Excellence [NICE]. Metastatic malignant disease of unknown primary origin in adults: diagnosis and management. Available via: https://www.nice.org.uk/guidance/cg104 (2010). Accessed January 2025.

LinkOut - more resources